Vanda Pharmaceuticals (NASDAQ: VNDA) just announced that it has received FDA-approval for its new drug known as BYSANTI. The drug is meant to treat Bipolar I manic episodes as well as Schizophrenia ...

Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved BYSANTI™ (milsaperidone) tablets, a first line therapy for the acute treatment ...

By Sneha S K and Kunal Das Feb 20 (Reuters) - The U.S. Food and Drug Administration has approved Vanda Pharmaceuticals' drug for the treatment of two serious mental health conditions, the company said ...

Vanda Pharmaceuticals received approval from the Food and Drug Administration for its treatment of a type of bipolar disorder as well as schizophrenia. The biopharmaceutical company said Friday ...

Vanda Pharmaceuticals had 9% revenue growth and heavy losses with a 1.4x sales valuation and a PDUFA date. Check out why VNDA stock is downgraded to hold.

The FDA has set a Feb. 21 target decision on the Bysanti NDA. ・Vanda submitted the NDA in March 2025 for Bysanti to treat acute bipolar I disorder and schizophrenia. ・In May, the FDA said the ...

A series of increasing buyout offers has failed to convince Vanda's board of directors that the company should sell itself. After receiving "unsolicited" buyout proposals from Michigan-based CDMO ...

Vanda Pharmaceuticals (NASDAQ: VNDA) has secured FDA approval for its new drug, BYSANTI (milsaperidone), marking a ...

B. Riley has initiated coverage of Vanda Pharmaceuticals (VNDA) at buy saying that the company is currently trading at a valuation that is a "historic discount" and is "untenable." The firm has a ...

Once again, Vanda Pharmaceuticals is challenging the FDA in court. This time, the company says the agency failed to give its application for Hetlioz in jet lag disorder a proper hearing after the FDA ...